Outcomes of Strabismus Surgery Following Teprotumumab Therapy.
Am J Ophthalmol
; 262: 186-191, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38191066
ABSTRACT
PURPOSE:
To investigate the results of patients undergoing surgical treatment for strabismic diplopia in thyroid eye disease (TED) following teprotumumab.DESIGN:
Multicenter, retrospective, case series.METHODS:
We report 28 patients who underwent extraocular muscle surgery for strabismic diplopia after treatment with teprotumumab at 7 different academic centers. Elapsed time from last teprotumumab dose to the date of surgery, previous orbital decompression, primary preoperative horizontal and vertical deviation, surgical procedure, and 2-month postoperative results were collected from the patient records.RESULTS:
Sixteen (57%) patients were diplopia-free after 1 surgery. Three (11%) chose prism spectacles to correct residual diplopia, 2 (7%) used compensatory head posture to resolve diplopia, and 1 (4%) had intermittent diplopia and was functionally improved (choosing no prisms or further surgery). These were considered treatment successes. Three (11%) patients required reoperation, and all were diplopia-free after their second procedure.CONCLUSIONS:
Most patients requiring surgery for strabismic diplopia following teprotumumab achieve good outcomes with success rates comparable to series published before the availability of teprotumumab.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Estrabismo
/
Diplopia
/
Oftalmopatia de Graves
/
Anticorpos Monoclonais Humanizados
/
Músculos Oculomotores
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article